Epzicom and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Epzicom (abacavir sulfate; lamivudine), especially for people who are male, 50-59 old, have been taking the drug for 6 - 12 months also take Truvada, and have Pain.

The phase IV clinical study analyzes which people have Mobility decreased when taking Epzicom. It is created by eHealthMe based on reports of 4,877 people who have side effects when taking Epzicom from the FDA, and is updated regularly.

What is Epzicom?

Epzicom has active ingredients of abacavir sulfate; lamivudine. It is often used in hiv infection. eHealthMe is studying from 4,937 Epzicom users. Check the latest studies of Epzicom.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,775 drugs and 1,635 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Aug, 11, 2026

4,877 people reported to have side effects when taking Epzicom.
Among them, 60 people (1.23%) have Mobility decreased.

Among these 60 people:

How long have people been on Epzicom when they have Mobility decreased? *

What is the gender of people who have Mobility decreased when taking Epzicom? *

female: 36.67 %
male: 63.33 %

What is the age of people who have Mobility decreased when taking Epzicom? *

What are other drugs people take besides Epzicom? *

What are other side effects people have besides Mobility decreased? *

Emotional Distress: 51 people, 85.00%
Pain: 51 people, 85.00%
Stress And Anxiety: 49 people, 81.67%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 48 people, 80.00%
Chronic Kidney Disease: 27 people, 45.00%
Fatigue (feeling of tiredness): 22 people, 36.67%
Depression: 19 people, 31.67%
Osteoporosis (bones weak and more likely to break): 19 people, 31.67%
Bone Density Decreased: 18 people, 30.00%
Acute Kidney Failure: 18 people, 30.00%

What are the existing conditions these people have? *

Pain: 7 people, 11.67%
Diarrhea: 5 people, 8.33%
High Blood Pressure: 5 people, 8.33%
Hepatic Neoplasm Malignant (liver cancer): 4 people, 6.67%
Bipolar Disorder (mood disorder): 3 people, 5.00%
Hypersensitivity: 3 people, 5.00%
Indigestion: 3 people, 5.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 5.00%
Insomnia (sleeplessness): 3 people, 5.00%
Rashes (redness): 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Epzicom and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epzicom:

Epzicom (4,937 reports)

Browse all side effects of Epzicom:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,775 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,635 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on abacavir sulfate; lamivudine (the active ingredients of Epzicom) and Epzicom (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.